GSE213504 Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies
Conclusion: Patient-derived tumoroids from high-grade GEP-NENs represent a relevant model to screen drug sensitivities of individual patients within clinically relevant timespans and provide novel functional insights into drug-induced stress responses. Clinical patient response to standard-of-care chemotherapeutics matches with drug sensitivities of PD tumoroids. Together, our findings provide a functional precision oncology approach for gathering patient-centered subsidiary treatment information that will potentially increase therapeutic opportunities in the framework of personalized medicine. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - March 1, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed < em > MGMT < /em > -methylated malignant glioma
CONCLUSIONS: The addition of acetazolamide is safe and tolerable in GBM patients receiving standard TMZ. Survival results compare favorably to historical data from randomized trials in patients with MGMT promoter-methylated GBM and support examination of acetazolamide in a randomized trial. BCL-3 expression is a potential biomarker for prognosis in GBM or for patients more likely to benefit from TMZ.PMID:38420615 | PMC:PMC10901541 | DOI:10.1093/noajnl/vdae014 (Source: Adv Data)
Source: Adv Data - February 29, 2024 Category: Epidemiology Authors: Riley K Driscoll Sean B Lyne David J Voce Stefania Maraka Vinai Gondi Steven J Chmura Karan S Dixit Priya U Kumthekar Theodore G Karrison Peter Pytel John M Collins Roger Stupp Ryan T Merrell Rimas V Lukas Bakhtiar Yamini Source Type: research
Peritumoral brain zone in glioblastoma: biological, clinical and mechanical features
Glioblastoma is a highly aggressive and invasive tumor that affects the central nervous system (CNS). With a five-year survival rate of only 6.9% and a median survival time of eight months, it has the lowest survival rate among CNS tumors. Its treatment consists of surgical resection, subsequent fractionated radiotherapy and concomitant and adjuvant chemotherapy with temozolomide. Despite the implementation of clinical interventions, recurrence is a common occurrence, with over 80% of cases arising at the edge of the resection cavity a few months after treatment. The high recurrence rate and location of glioblastoma indica...
Source: Frontiers in Immunology - February 29, 2024 Category: Allergy & Immunology Source Type: research
Impact of Reirradiation Utilizing Fractionated Stereotactic Radiotherapy for Recurrent Glioblastoma
CONCLUSIONS: Reirradiation utilizing FSRT was associated with improved PFS and OS after GBM recurrence compared to the control group who did not receive additional irradiation.PMID:38406061 | PMC:PMC10894660 | DOI:10.7759/cureus.53001 (Source: Cancer Control)
Source: Cancer Control - February 26, 2024 Category: Cancer & Oncology Authors: Lisa B Shields Patrick O'Dell Michael W Daniels Parag R Sevak Hilary A Highfield Kaylyn D Sinicrope David A Sun Aaron C Spalding Source Type: research
Cancers, Vol. 16, Pages 936: Activation of Epstein & ndash;Barr Virus & rsquo; Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide
Cancers, Vol. 16, Pages 936: Activation of Epstein–Barr Virus’ Lytic Cycle in Nasopharyngeal Carcinoma Cells by NEO212, a Conjugate of Perillyl Alcohol and Temozolomide
Cancers doi: 10.3390/cancers16050936
Authors:
Hannah Hartman-Houstman
Steve Swenson
Radu O. Minea
Uttam K. Sinha
Ming-Fu Chiang
Thomas C. Chen
Axel H. Schönthal
The Epstein&ndash;Barr virus (EBV) is accepted as a primary risk factor for certain nasopharyngeal carcinoma (NPC) subtypes, where the virus persists in a latent stage which is thought to contribute to tumorigenesis. Current treatments are sub-optimal...
Source: Cancers - February 26, 2024 Category: Cancer & Oncology Authors: Hannah Hartman-Houstman Steve Swenson Radu O. Minea Uttam K. Sinha Ming-Fu Chiang Thomas C. Chen Axel H. Sch önthal Tags: Article Source Type: research
DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma
ConclusionWe propose that combining the DIAPH3 expression with MGMT methylation could offer a better prediction of survival and more adapted postsurgical treatment for patients with MGMT-methylated glioblastoma. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - February 22, 2024 Category: Cancer & Oncology Source Type: research
Long acting tariquidar loaded stearic acid-modified hydroxyapatite enhances brain penetration and antitumor effect of temozolomide
Eur J Pharm Biopharm. 2024 Feb 19:114231. doi: 10.1016/j.ejpb.2024.114231. Online ahead of print.ABSTRACTTemozolomide (TMZ) is the first line chemotherapy for glioblastoma (GBM) treatment, but the P-glycoprotein (P-gp) expressed in blood-brain barrier (BBB) will pump out TMZ from the brain leading to decreased TMZ concentration. Tariquidar (TQD), a selective and potent P-gp inhibitor, may be suitable for combination therapy to increase concentration of TMZ in brain. Hydroxyapatite (HAP) is a biodegradable material with sustained release characteristics, and stearic acid surface-modified HAP (SA-HAP) can increase hydrophobi...
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 21, 2024 Category: Drugs & Pharmacology Authors: Cheng-Ping Yu Shang-Wen Lin Jui-Chen Tsai Yan-Jye Shyong Source Type: research
Long acting tariquidar loaded stearic acid-modified hydroxyapatite enhances brain penetration and antitumor effect of temozolomide
Eur J Pharm Biopharm. 2024 Feb 19:114231. doi: 10.1016/j.ejpb.2024.114231. Online ahead of print.ABSTRACTTemozolomide (TMZ) is the first line chemotherapy for glioblastoma (GBM) treatment, but the P-glycoprotein (P-gp) expressed in blood-brain barrier (BBB) will pump out TMZ from the brain leading to decreased TMZ concentration. Tariquidar (TQD), a selective and potent P-gp inhibitor, may be suitable for combination therapy to increase concentration of TMZ in brain. Hydroxyapatite (HAP) is a biodegradable material with sustained release characteristics, and stearic acid surface-modified HAP (SA-HAP) can increase hydrophobi...
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 21, 2024 Category: Drugs & Pharmacology Authors: Cheng-Ping Yu Shang-Wen Lin Jui-Chen Tsai Yan-Jye Shyong Source Type: research
Cancers, Vol. 16, Pages 863: Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity
Collis
Glioblastoma is an aggressive, incurable brain cancer with poor five-year survival rates of around 13% despite multimodal treatment with surgery, DNA-damaging chemoradiotherapy and the recent addition of Tumour Treating Fields (TTFields). As such, there is an urgent need to improve our current understanding of cellular responses to TTFields using more clinically and surgically relevant models, which reflect the profound spatial heterogeneity within glioblastoma, and leverage these biological insights to inform the rational design of more effective therapeutic strategies incorporating TTFields. We have recently ...
Source: Cancers - February 21, 2024 Category: Cancer & Oncology Authors: Callum G. Jones Aurelie Vanderlinden Ola Rominiyi Spencer J. Collis Tags: Article Source Type: research
Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide
This study established a TMZ-resistant U251 (U251-TMZ) cell line by exposing it to increasing doses of TMZ in vitro. We focused on the DNA methyltransferase 3B (DNMT3B) gene, phosphorylated Akt (p-Akt), total Akt (t-Akt), phosphorylated PI3K (p-PI3K), and total PI3K (t-PI3K) protein expression. Results showed that the DNMT3B gene was significantly upregulated in the U251-TMZ cell line. The p-Akt and p-PI3K protein expression in U251-TMZ cells was also significantly elevated. Moreover, we found that DNMT3B downregulation was correlated with the increased chemosensitivity of GBM cells to TMZ. LY294002 suppressed the PI3K/Akt...
Source: Molecular Neurobiology - February 17, 2024 Category: Neurology Source Type: research
Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors
ConclusionThese findings suggest that the type of PJP prophylaxis does not significantly affect the risk for hematologic toxicity in brain tumor patients receiving radiation and temozolomide. Additional studies are merited to evaluate the higher rate of neutropenia in patients on TMP/SMX observed in this study. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 16, 2024 Category: Cancer & Oncology Source Type: research
Molecules, Vol. 29, Pages 840: Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy
In this study, we have investigated the synergistic effects of combining temozolomide with doxorubicin, a chemotherapeutic agent widely used against various cancers. Our experiments, conducted on both temozolomide-sensitive (U87) and -resistant cells (GBM43 and GBM6), have demonstrated a synergistic inhibition of brain cancer cells with this combination treatment. Notably, the combination enhanced doxorubicin uptake and induced higher apoptosis in temozolomide-resistant GBM43 cells. The significance of our findings lies in the potential application of this combination treatment, even in cases of temozolomide resistance. De...
Source: Molecules - February 14, 2024 Category: Chemistry Authors: Laxmi Dhungel Mandy E. Rowsey Cayla Harris Drazen Raucher Tags: Article Source Type: research
Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent
In this study, a series of novel 4-Aryl-4H-chromene derivatives (D1-D31) were designed and synthesized by integrating quinoline heterocycle to crolibulin template molecule based on the strategy of molecular hybridization. One of these compounds D19 displayed positive antiproliferative activity against U87 cancer cell line (IC50 = 0.90 ± 0.03 μM). Compound D19 was verified as the microtubule-targeting agent through downregulating tubulin related genes of U87 cells, destroying the cytoskeleton of tubulins and interacting with the colchicine-binding site to inhibit the polymerization of tubulins by transcriptome analysis, i...
Source: European Journal of Medicinal Chemistry - February 13, 2024 Category: Chemistry Authors: Haoyi Yang Dongyu Zhang Ziyang Yuan Haishi Qiao Zhuolu Xia Feng Cao Yuanyuan Lu Feng Jiang Source Type: research
GSE255581 GDNF/GFRA1 signaling contributes to chemo- and radioresistance in glioblastoma
In this study we first discovered glial-cell derived neurotrophic factor (GDNF) to be upregulated in patient-derived glioblastoma spheroid cultures after chemotherapeutic temozolomide (TMZ) treatment, through RNA-Seq experiments. Therefore, we investigated the role of the GDNF/GDNF receptor alpha 1 (GFRA1) signaling pathway as a resistance mechanism to chemotherapy with temozolomide and lomustine as well as irradiation using patient-derived glioblastoma spheroid cultures. With qPCR experiments we showed a consistent upregulation of GDNF and its primary receptor GFRA1 following all three lines of treatment. Moreover, CRISPR...
Source: GEO: Gene Expression Omnibus - February 13, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Pediatric extra-axial glioblastoma with bone invasion leading to a subcutaneous mass: A case report
CONCLUSION: We present the first case of extra-axial p-GBM in a young patient, which remarkably led to the destruction of the bone and finally resulted in a sizable parietal subcutaneous lesion in the absence of prior surgery or radiation.PMID:38344102 | PMC:PMC10858785 | DOI:10.25259/SNI_809_2023 (Source: Surgical Neurology International)
Source: Surgical Neurology International - February 12, 2024 Category: Neurosurgery Authors: Marouane Hammoud Oualid Mohammed Hmamouche Faycal Lakhdar Mohammed Benzagmout Khalid Chakour Mohammed El Faiz Chaoui Source Type: research
